Guardian Pharmacy Services, Inc. (NYSE:GRDN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $42.8333.

A number of equities analysts recently commented on GRDN shares. Truist Financial boosted their target price on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Bank of America lifted their price target on Guardian Pharmacy Services from $42.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Wall Street Zen cut Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Raymond James Financial reiterated an “outperform” rating and issued a $40.00 price objective on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Finally, UBS Group reissued a “buy” rating on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th.

Institutional Trading of Guardian Pharmacy Services

Institutional investors have recently modified their holdings of the stock. CSM Advisors LLC raised its stake in Guardian Pharmacy Services by 40.9% during the 3rd quarter. CSM Advisors LLC now owns 135,665 shares of the company’s stock worth $3,559,000 after acquiring an additional 39,360 shares in the last quarter. SG Americas Securities LLC lifted its position in Guardian Pharmacy Services by 274.9% in the fourth quarter. SG Americas Securities LLC now owns 19,017 shares of the company’s stock valued at $572,000 after acquiring an additional 13,945 shares during the last quarter. Aristotle Capital Boston LLC boosted its stake in Guardian Pharmacy Services by 58.5% in the third quarter. Aristotle Capital Boston LLC now owns 649,463 shares of the company’s stock valued at $17,035,000 after acquiring an additional 239,790 shares in the last quarter. Jennison Associates LLC acquired a new position in Guardian Pharmacy Services in the fourth quarter valued at $3,489,000. Finally, TimesSquare Capital Management LLC grew its holdings in shares of Guardian Pharmacy Services by 21.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 1,048,136 shares of the company’s stock worth $31,538,000 after purchasing an additional 187,963 shares during the last quarter.

Guardian Pharmacy Services Stock Down 3.9%

Shares of Guardian Pharmacy Services stock opened at $39.78 on Wednesday. Guardian Pharmacy Services has a 52-week low of $19.30 and a 52-week high of $44.00. The company has a 50 day moving average of $39.40 and a 200 day moving average of $35.53. The company has a market capitalization of $1.98 billion, a P/E ratio of 47.93, a P/E/G ratio of 2.71 and a beta of 0.05.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.24 by $0.05. Guardian Pharmacy Services had a net margin of 3.64% and a return on equity of 30.72%. The company had revenue of $336.60 million during the quarter, compared to analysts’ expectations of $329.89 million. During the same quarter in the previous year, the business posted $0.22 EPS. The firm’s revenue was up 2.2% on a year-over-year basis. As a group, research analysts anticipate that Guardian Pharmacy Services will post 1.18 earnings per share for the current fiscal year.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.